吗琳基(4-哌啶)甲酮盐酸盐 | 94467-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 吗琳基(4-哌啶)甲酮盐酸盐
• 中文别名: 吗琳基(4-哌啶)甲酮
• 英文名称: morpholino(piperidine-4-yl)methanone hydrochloride
• 英文别名: 4-(piperidine-4-carbonyl)morpholine hydrochloride；1-(4-piperidinylcarbonyl)morpholine hydrochloride；4-(morpholine-4-carbonyl)piperidinium chloride；morpholino(piperidin-4-yl)methanone hydrochloride salt；Morpholino(piperidin-4-yl)methanone hydrochloride；morpholin-4-yl(piperidin-4-yl)methanone;hydrochloride
• CAS: 94467-73-9
• 化学式: C₁₀H₁₈N₂O₂*ClH
• mdl: MFCD05864747
• 分子量: 234.726
• InChiKey: YODDNPCNUDVZEO-UHFFFAOYSA-N

物化性质

• 熔点：
  279-286

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  吗琳基(4-哌啶)甲酮盐酸盐 、 (S)-4-((tert-butoxycarbonyl)amino)-5-phenylpentanoic acid 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Structure−Activity Relationships of 6-Methyl-benzo[b]thiophene-2-carboxylic Acid (1-{(S)-1-Benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl}cyclopentyl)amide, Potent Antagonist of the Neurokinin-2 Receptor

  摘要：

  As part of a project aimed at the identification of a series of small, orally available antagonists for the hNK(2) receptor, starting from one of our capped dipeptide libraries, we succeeded in the chemical optimization of the first identified leads, finally producing a class of molecules with significant activity in our animal model after iv administration. We herein report the results of further chemical modifications made to reduce the overall peptide character of this series and the consequent improvement of their in vivo antagonist activity. The present work identified 6-methylbenzo[b]thiophene-2-carboxylic acid (1-{(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl}cyclopentyl)amide (10i), endowed with subnanomolar potency in all the in vitro tests and being highly potent and of long duration upon in vivo testing after both iv and id dosing.

  DOI：

  10.1021/jm100176s
• 作为产物：
  描述：

  morpholino(pyridin-4-yl)methanone 在 1,1,2-三氯乙烷 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 18.0h， 以96%的产率得到吗琳基(4-哌啶)甲酮盐酸盐
  参考文献：
  名称：

  在温和条件下吡啶核的高效Pd–C催化加氢

  摘要：

  在存在ClCH 2 CHCl 2的情况下，开发了对4-吡啶羧甲酰胺盐酸盐直接作用的4-吡啶甲酰胺的Pd-C协同催化氢化反应。它通过在温和条件下使用低成本的Pd-C催化剂，为吡啶核的高效加氢提供了一种新的策略。

  DOI：

  10.1016/j.tet.2009.08.011

文献信息

• [EN] 6H-THIENO`2, 3-B!PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)<br/>[FR] DERIVES DE 6H-THIENO`2,3-B!PYRROLE EN TANT QU'ANTAGONISTES DE LA GONADOLIBERINE (GNRH)
  申请人：ASTRAZENECA AB

  公开号：WO2004018480A1

  公开（公告）日：2004-03-04

  The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

  这项发明涉及一组新型噻吩-吡咯烷化合物的化学式（I）：其中：R1、R2、R3、R4和R5如规范中定义，这些化合物可用作促性腺激素释放激素拮抗剂。该发明还涉及所述化合物的药物配方、使用所述化合物的治疗方法以及所述化合物的制备方法。
• [EN] TRPML MODULATORS<br/>[FR] MODULATEURS DE TRPML
  申请人：CASMA THERAPEUTICS INC

  公开号：WO2021127337A1

  公开（公告）日：2021-06-24

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、药学上可接受的组合物以及使用这些化合物的方法。
• [EN] BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS<br/>[FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES EN TANT QUE MODULATEURS DE GPR119
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011140160A1

  公开（公告）日：2011-11-10

  Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R2 and R4 are defined herein, are provided which are GPR119 G protein- coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  结构式I的新化合物：或其对映体、二对映体、互变异构体、前药或盐，其中A、D、Di、E、J、L、n、Q、R2和R4在此处被定义，提供了这些化合物是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病的进展方面是有用的。因此，本公开还涉及包含这些新化合物的组合物和使用任何这些新化合物或包含任何这些新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或症状的方法。
• 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR101555033B1

  公开（公告）日：2015-09-23

  본 발명은 신규한 메타논 유도체, 이의 제조방법, 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 신규한 메타논 유도체, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염은 RIPK1(Receptor-interacting serine/threonine-protein kinase 1)의 억제 효과가 뛰어나므로, 이를 유효성분으로 함유하는 조성물은 색소성 망막염 (RP), 레베르 선천 흑암시 (LCA), 스타가르트병, 어셔 증후군, 맥락막 결여, 로드-콘 또는 콘-로드 디스트로피, 섬모병증, 미토콘드리아 장애, 진행성 망막 위축증, 퇴행성 망막 질환, 노화-관련된 황반 변성 (AMD), 습성 AMD, 건성 AMD, 지도상 위축증, 가족형 또는 획득 황반병증, 망막 광수용체 질환, 망막 색소 상피-계 질환, 당뇨병성 망막증, 낭포성 황반 부종, 포도막염, 망막박리, 외상성 망막 손상, 의원성 망막 손상, 황반 원공, 황반 모세관확장증, 신경절 세포 질환, 시신경 세포 질환, 녹내장, 시신경병증, 허혈성 망막 질환, 미숙아 망막증, 망막 혈관 폐색, 가족형 마크로아뉴리즘, 망막 혈관 질환, 안혈관 질환, 녹내장으로 인한 망막신경세포 퇴화, 또는 허혈성 시신경병증 등의 망막 질환의 예방 또는 치료용 약학적 조성물로 유용하게 사용될 수 있다.

  本发明涉及一种新型的甲酮衍生物，其制备方法，以及用作视网膜疾病的预防或治疗药物组合物，根据本发明，由于新型的甲酮衍生物，其光学异构体或药学上可接受的盐具有出色的RIPK1（受体相互作用丝氨酸/苏氨酸蛋白激酶1）抑制作用，因此包含其作为有效成分的组合物可用作色素性视网膜炎（RP），勒贝尔先天性黑暗症（LCA），斯塔加特病，阿什尔综合征，脉络膜缺陷，罗德-锥或锥-罗德萎缩症，圆锥细胞病，线粒体疾病，进行性视网膜萎缩症，变性性视网膜疾病，与衰老相关的黄斑变性（AMD），湿性AMD，干性AMD，地图样萎缩症，家族性或获得性黄斑病变，视网膜光感受器疾病，视网膜色素上皮相关疾病，糖尿病性视网膜病变，囊性黄斑水肿，葡萄膜炎，视网膜脱离，创伤性视网膜损伤，原发性视网膜损伤，黄斑囊肿，黄斑脉络膨胀症，神经节细胞疾病，视神经细胞疾病，青光眼，视神经病变，缺血性视网膜疾病，未成熟婴儿视网膜病变，视网膜血管闭塞，家族性巨动脉瘤，视网膜血管疾病，眼内血管疾病，由青光眼引起的视神经细胞退化，或缺血性视神经病变等视网膜疾病的预防或治疗药物组合物可被有效地使用。
• [EN] PYRROLE DERIVATIVES AS GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONISTS<br/>[FR] DERIVES DE PYRROLE UTILISES EN TANT QU'ANTAGONISTES DE L'HORMONE LIBERANT DE LA GONADOTROPHINE (GNRH)
  申请人：ASTRAZENECA AB

  公开号：WO2005079805A1

  公开（公告）日：2005-09-01

  The invention relates to a group of novel thieno-pyrrole compounds of formula (I) wherein: R1, R2, R3, R4 M, and R5 are as defined in the specification, as inter alia, gonadotrophin releasing hormone antagonists. Novel compounds of formula (I) are also claimed. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

  这项发明涉及一组新型噻吩-吡咯烯化合物，其化学式为（I），其中：R1、R2、R3、R4、M 和 R5 如规范中所定义，作为促性腺激素释放激素拮抗剂。化学式（I）的新型化合物也被要求。该发明还涉及所述化合物的药物配方、使用所述化合物的治疗方法以及所述化合物的制备方法。